Enveric Biosciences reported a net loss of $7.21 million for the nine months ended September 30, 2026, compared to $6.58 million in the prior year period, driven by increased research and development costs. The company strengthened its cash position to $5.61 million through various financing activities, including private placements and warrant exercises, resulting in a total shareholders' equity of $5.73 million.
Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.
Term
Q3 2026
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric